AONN+ Conference Abstracts

Ibrutinib is a first-in-class, once-daily inhibitor of BTK approved in the United States for treatment of CLL/SLL. RESONATE-2 is a phase 3 study comparing first-line ibrutinib versus chlorambucil in patients with CLL/SLL. Primary results (median follow-up, 18.4 months) demonstrated ibrutinib reduced risk of progressive disease (PD) or death by 84% (Burger, 2015).

Today there are ever-increasing challenges surrounding breast cancer care. The ongoing disparities in delivering cancer care continue to impact our nation as a whole, and, more importantly, for both patients and providers in our local communities.

Currently, pancreatic cancer (PC) is the fourth leading cause of cancer mortality in the United States. However, with the lack of early detection tests and treatment options, it is estimated that PC may move to the second leading cause of cancer death in the United States by 2020 or even earlier.

The tumor board, or multidisciplinary cancer conference (MCC), is the foundation of high-value multidisciplinary oncology care through coordinating teams of specialists.

According to Morgan, “Lung Cancer is the leading cause of cancer-related death in the United States, claiming more lives than colon, breast, and prostate cancer combined.”

The multidisciplinary cancer conference (MCC) plays an integral role in optimizing patient outcomes in today’s increasingly complex world of cancer care.

Accessing chimeric antigen receptor (CAR) T-cell clinical trials for relapsed and refractory B-cell acute lymphoblastic leukemia (ALL) is challenging for pediatric patients who have experienced a relapse of B-cell ALL or have been refractory to standard therapy.

The Johns Hopkins Department of Obstetrics & Gynecology, Division of Gynecologic Oncology, Sibley Memorial Hospital, performs more than 500 surgeries annually.

The Cancer Support Community (CSC) has designed a patient/provider discussion tool for patients with chronic myeloid leukemia (CML).

Each woman’s risk of developing breast cancer is different and depends on her lifestyle, family health history, and other factors. The American Cancer Society considers women who have a lifetime risk assessment of 20% or greater to be at high risk for breast cancer.